DAY 3 - Sunday, February 5, 2012
ANNUAL GLAUCOMA SYMPOSIUM
Trials provide practical perspectives on glaucoma
San Francisco—Results from randomized, controlled clinical trials provide clear evidence that for most patients, glaucoma is an IOP-sensitive optic neuropathy for which lowering IOP is effective in slowing or arresting progression, said Gregory L. Skuta, MD, in his presentation of the Shaffer-Hetherington-Hoskins Lecture at the 16th annual Glaucoma Symposium during Glaucoma 360. » MORE
Future: More patients, lower fees, but continued rewards
San Francisco—Trends in demographics and economics indicate ophthalmologists face important challenges ahead in their efforts to deliver quality patient care, but these burdens cannot overshadow the personal rewards reaped from the profession, said H. Dunbar Hoskins Jr., MD. » MORE
Relative safety establishes role for canaloplasty
San Francisco—Canaloplasty is an effective procedure for achieving sustained lowering of IOP and medication burden in patients with open-angle glaucoma, and its safety profile makes it a good contender for competing with trabeculectomy, said Richard A. Lewis, MD. » MORE
Glaucoma care sees expansion of surgical options
San Francisco—Thanks to recent advances, surgical management of glaucoma may be entering a new age in which it will be possible to tailor the procedure to individual patients and preserve vision with fewer complications than with trabeculectomy, said Robert L. Stamper, MD. » MORE
New world of generics brings medical challenges
San Francisco—New medications for treating glaucoma may be on the horizon, but in 2012, prostaglandin analogues are still the leading class for lowering IOP and generics are taking on a more prominent role, said Andrew G. Iwach, MD. » MORE
DISCLAIMER:
This information has been independently developed and provided by the editors of Ophthalmology Times. The sponsor does not endorse and is not responsible for the accuracy of the content or for practices or standards of non-sponsor sources.
|
